House sustains President's embryonic stem cell veto
This article was originally published in Clinica
Executive Summary
The chance for stem cell legislation is over for this year. On July 19 the US House failed to muster the two-thirds margin needed to override a presidential veto of a bill expanding the number of stem cell lines available for federally funded research. The House vote was 235 to 193, the same day President Bush vetoed the bill saying it would finance "the deliberate destruction of embryos".
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.